175 related articles for article (PubMed ID: 31312929)
1. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
4. Pixantrone: novel mode of action and clinical readouts.
Minotti G; Han H; Cattan V; Egorov A; Bertoni F
Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
[TBL] [Abstract][Full Text] [Related]
6. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Keating GM
Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832
[TBL] [Abstract][Full Text] [Related]
7. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Heyman B; Rizzieri D; Adams DJ; De Castro C; Diehl L; Li Z; Moore J; Beaven A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):679-686. PubMed ID: 30166257
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
[TBL] [Abstract][Full Text] [Related]
10. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Jamal-Hanjani M; Pettengell R
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
[TBL] [Abstract][Full Text] [Related]
12. The role of mitoxantrone in non-Hodgkin's lymphoma.
Armitage JO
Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R; Sebban C; Zinzani PL; Derigs HG; Kravchenko S; Singer JW; Theocharous P; Wang L; Pavlyuk M; Makhloufi KM; Coiffier B
Br J Haematol; 2016 Sep; 174(5):692-9. PubMed ID: 27118109
[TBL] [Abstract][Full Text] [Related]
14. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
15. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
El-Helw LM; Hancock BW
Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
17. Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
Cencini E; Fabbri A; Schiattone L; Gentili F; Mazzei MA; Bocchia M
Acta Clin Belg; 2018 Dec; 73(6):408-412. PubMed ID: 29212420
[TBL] [Abstract][Full Text] [Related]
18. Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2016 Aug; 29(8):1270-8. PubMed ID: 27420111
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]